Insider Buying Fuels Hope for Hepion Pharmaceuticals’ Liver Therapy Upside
Insider buying spurs hope for Hepion Pharmaceuticals’ liver‑disease drugs—learn how executives’ $0.04 purchases signal a potential rebound and high‑risk upside.
4 minutes to read